125742 S1 M1 1.9.2 ped studies deferral req

Pfizer Documents (PHMPT/FDA)

Pfizer Bla Submission

Pfizer 16 Plus Documents

3

Download PDF ↗ Live URL (may be dead)

Document text

COVID -19Vaccine (BNT162 ,PF-07302048 )
BB-IND 019736
Agreed Initial Pediatric Study Plan
PFIZER CONFIDENTIAL
Page 1ATTACHMENT A—DEFERRAL REQUEST
Product Name COVID -19 Vaccine (BNT162, PF -07302048)
IND number 019736
Applicant BioNTech
Proposed Initial Indication Active immunization against COVI D-19 in 
individuals ≥16years of age
Future Supplemental Indications Active immunization against COVI D-19 in children 
and adolescents 12through 15 years of age; Active 
immunization against COVID -19 in children and 
infants <12years of age .
1.  Pediatric age group sfor whom 
deferrals are requestedAdolescents, children ,and infants 15 y ears of age 
and y ounger
2. Reason for requesting deferral of 
pediatric studies (address each 
age group separately  and for 
each group choose all that 
apply ):Adeferral of the evaluation of the COVID -19 
vaccine in individuals ≤15 years of age is requested 
based on the following Criteria for Deferral 
(Section 505B (a)(4)(A)(i)(I) of the Act): “Pediatric 
studies should be delay ed until additional safety  or 
effectiveness data have been collected” and “The 
drug or biological product will be read y for approval 
for use in adults before pediatric studies are 
complete.”
Adequate evidence of safety  and efficacy  has been 
established in the pivotal study  C4591001 in 
individuals ≥16 y ears of age to allow Emergency  
Use Authorization in that age group. 
Study C4591001 includes subject s12 through 17 
years of age.  It is appropriat e to defer studies in 
children 5 to 11 y ears of age until adequate safet y 
and immunogenicit y information is available in 
12-through 15 -year-old children and adolescents.  I t 
would then be appropriate to defer further age -de-
escalation until adequate safet y data is available in 
5-through 11 -year-old children.
090177e196ade61b\Approved\Approved On: 02-Apr-2021 12:38 (GMT)
FDA-CBER-2021-5683-1150753
COVID -19Vaccine (BNT162 ,PF-07302048 )
BB-IND 019736
Agreed Initial Pediatric Study Plan
PFIZER CONFIDENTIAL
Page 23. Pediatric age group(s) not 
included in the deferral requestChildren and adolescents 16 through 17 years of age
4. Reason for not including the 
pediatric age group(s) listed in 
number 3 in the deferral request Study  C4591001 includes subjects 16 through 17 
years of age
5. Has a pediatric plan been 
submitted to the Agency .Yes
6. Suggested deferred date for 
initiation and submission of 
studiesThe estimated initiation date for Study C4591007, a 
safet y and effectiveness study in children <11 years 
of age , is no later than April 2021.
090177e196ade61b\Approved\Approved On: 02-Apr-2021 12:38 (GMT)
FDA-CBER-2021-5683-1150754
Document Approval Record
Document Name:	

 	!!"#$%&"
%
'(#""	
("	"!)
(*
	#
Document Title:	

 	!!"#$%&"
%
'(#""	
("	"!)
(*
	#
Signed By: Date(GMT) Signing Capacity
+	,"#-

./
"	 %&001 '
	*%	"%&&2	
090177e196ade61b\Approved\Approved On: 02-Apr-2021 12:38 (GMT)
FDA-CBER-2021-5683-1150755